Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2017-10-17 Share Issue/Capital Cha…
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE
Share Issue/Capital Change Classification · 1% confidence The document is an official communication ('Informazione Regolamentata') from Pharmanutra S.p.A. The subject ('Oggetto') is 'CAPITALE SOCIALE' (Share Capital) and the title is 'COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE' (Communication of Share Capital Variation). The text details the change in the number of shares following the exercise of warrants and conversion of Price Adjustment Shares, presenting a table comparing the previous and current share capital structure. This directly relates to changes in the company's capital structure, which aligns with the definition of 'Capital/Financing Update' (CAP). Although it involves share changes, it is a formal announcement of a capital structure adjustment rather than a general share repurchase (POS) or a general share issue (SHA), making CAP the most precise fit for a capital structure change event.
2017-10-17 Italian
COMUNICATO STAMPA CONVERSIONE DELLE PRICE ADJUSTMENT SHARE
Share Issue/Capital Change Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. titled "COMUNICATO STAMPA CONVERSIONE DELLE PRICE ADJUSTMENT SHARE" (Press Release Conversion of Price Adjustment Shares). It details a corporate action where specific shares are converted into ordinary shares based on a pre-defined price trigger (average price exceeding EUR 13.00 in September 2017). This action relates to capital structure changes and the issuance/conversion of shares. The key terms are 'conversione' (conversion), 'Price Adjustment Share', and 'azioni ordinarie' (ordinary shares). This fits best under 'Share Issue/Capital Change' (SHA), which covers changes in capital structure, including share conversions. It is not an Earnings Release (ER) as it focuses on a structural change, not periodic financial results. It is not a general Regulatory Filing (RNS) because a more specific category exists. It is not a Transaction in Own Shares (POS) as it is a conversion mechanism, not a buyback/sale. Therefore, SHA is the most appropriate classification.
2017-09-30 Italian
COMUNICATO STAMPA ESERCIZIO DEI WARRANT DI PHARMANUTRA S.P.A. PER IL PERIODO DAL 1 AL 29 SETTEMBRE 2017
Share Issue/Capital Change Classification · 1% confidence The document is an official communication ('COMUNICATO STAMPA') from Pharmanutra S.p.A. regarding the exercise of warrants ('ESERCIZIO DEI WARRANT') during a specific period in September 2017. It details the number of warrants exercised and the resulting shares issued. This type of announcement, concerning capital structure changes, financing instruments (warrants), and the resulting share issuance, aligns best with the 'Capital/Financing Update' category (CAP). While it results in a share issue (SHA), the primary focus is the execution/settlement of a financing mechanism (warrants), making CAP more precise than a general share issue announcement (SHA), which usually covers splits or new public offerings. It is not a full financial report (10-K, IR) or a simple dividend notice (DIV).
2017-09-30 Italian
Pharmanutra SpA approva la relazione semestrale al 30 giugno 2017
Report Publication Announcement Classification · 1% confidence The document is a press release from Pharmanutra S.p.A. announcing the approval of its consolidated half-year financial report as of June 30, 2017. While it contains summary financial tables (balance sheet and income statement), it explicitly states 'Vedi allegato' (See attachment) and mentions that the full report will be made available on the company website. According to the 'Menu vs Meal' rule, this is an announcement of a report rather than the full interim report itself. Therefore, it is classified as a Report Publication Announcement (RPA). H1 2017
2017-09-18 Italian
CS PHARMANUTRA CETILAR® DIVENTA MAIN SPONSOR DEL PARMA CALCIO 1913
Regulatory Filings Classification · 1% confidence The document is an official communication ('Informazione Regolamentata') from an Italian company (PharmaNutra S.p.A.) dated September 11, 2017. The subject ('Oggetto') is 'CS PHARMANUTRA CETILAR® DIVENTA MAIN SPONSOR DEL PARMA CALCIO' (PharmaNutra Cetilar becomes Main Sponsor of Parma Calcio). The text details a sponsorship agreement, which is a business development announcement, not a standard financial report (like 10-K, IR, or ER). It is a specific corporate event announcement. This type of announcement, detailing a significant commercial partnership or sponsorship, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is best classified as a general Regulatory Filing (RNS) as it is a formal communication to the market about a material event, or potentially a Capital/Financing Update (CAP) if the sponsorship involved significant capital outlay, but given the context of a sponsorship deal announcement, RNS is the most appropriate general regulatory disclosure category when a more specific one isn't available. Since it is a formal, market-disclosed communication about a business event, RNS is the best fit among the provided options, acting as a catch-all for significant, non-financial-statement disclosures.
2017-09-11 Italian
COMUNICATO STAMPA ESERCIZIO DEI WARRANT DI PHARMANUTRA S.P.A. PER IL PERIODO DAL 1 AL 31 AGOSTO 2017
Share Issue/Capital Change Classification · 1% confidence The document is a press release (COMUNICATO STAMPA) from Pharmanutra S.p.A. regarding the exercise of warrants during August 2017. It details the number of warrants exercised and the resulting new shares. This type of announcement, concerning capital structure changes related to financing instruments (warrants), fits best under the 'Capital/Financing Update' category. While it involves share issuance, the primary focus is the exercise mechanism of a financing tool rather than a general share issue announcement (SHA) or a buyback (POS). It is a specific corporate action related to capital structure, making CAP the most appropriate fit over the general RNS fallback.
2017-08-31 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.